Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Inv. presentation
Sorrento Therapeutics, Inc. (SRNE) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/18/2022 8-K Quarterly results
12/20/2019 8-K Quarterly results
12/09/2019 8-K Appointed a new director
Docs: "Schedule A",
"REGISTRATION RIGHTS AGREEMENT",
"SORRENTO Announces new board member SAN DIEGO, December 9th , 2019/GlobeNewswire/ -- Sorrento Therapeutics, Inc. announced today that Mr. Edgar Lee has been appointed to its Board of Directors. Mr. Lee is currently a Managing Director at Oaktree Capital Management. Mr. Lee founded and was the portfolio manager of Oaktree’ s $5.5bn Strategic Credit strategy. He was also the Chief Executive Officer and Chief Investment Officer of Oaktree’ s three business development companies including Oaktree Specialty Lending and Oaktree Strategic Income Corporations . Prior to joining Oaktree in 2007, Mr. Lee worked at UBS Investment Bank in Los Angeles and Lehman Brothers in New York. He received a B.A. degree in economics from Swarthmore College and his master’ s degree from Harvard University. Mr. Lee..."
08/08/2014 8-K Resignation/termination of a director, Appointed a new director
Docs: "Sorrento Therapeutics Appoints Douglas Ebersole to its Board of Directors San Diego, CA - August 8, 2014 - Sorrento Therapeutics, Inc. , a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of industry veteran Douglas Ebersole to its Board of Directors. Mr. Ebersole has over 25 years of broad business experience in industry as well as from consulting in a number of advisory roles, including as a former partner in a Silicon Valley law firm. Currently, Mr. Ebersole is an independent consultant and has worked primarily with PDL BioPharma since 2005. From 1992 to 2005, Mr. Ebersole served in various senior executive roles at PDL, including Senior Vice President - Corporate Development and Legal. During 2002, Mr. Ebers..."
03/11/2014 8-K Resignation/termination of a director, Appointed a new director
Docs: "Sorrento Therapeutics Appoints Mark Durand to its Board of Directors San Diego, CA - March 11, 2014 - Sorrento Therapeutics, Inc. , a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of industry veteran Mark W. Durand to its Board of Directors. Mr. Durand has nearly 28 years of broad pharmaceutical industry experience in a variety of leadership roles for both branded and generic drugs. Currently, Mr. Durand is an independent strategic consultant for pharmaceutical firms. Previously, he was the Chief Financial Officer and Senior Vice President Finance and Business Development for Watson Pharmaceuticals . Prior to that, he was Senior Vice President of Finance and Business Development at Teva Americas and served under ..."
02/03/2014 8-K Resignation/termination of a director, Appointed a new director
Docs: "Sorrento Therapeutics Welcomes Daniel Levitt as a Director to its Board San Diego, CA - February 3, 2014 - Sorrento Therapeutics, Inc. a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of Clinical Oncologist Daniel Levitt, M.D., Ph.D., as a member to its Board of Directors. He currently serves as Executive Vice President and Chief Medical Officer of CytRx Corporation. “Daniel's proven expertise overseeing the successful development of major oncology drugs will be invaluable to Sorrento as we advance our pipeline to address the unmet needs of cancer patients,” said Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento. Dr. Levitt commented, “I am excited to join Sorrento's Board of Directors at this piv..."
04/21/2011 8-K Form 8-K - Current report
02/05/2010 8-K Form 8-K - Current report
09/22/2009 8-K/A Form 8-K/A - Current report [Amend]
09/21/2009 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy